Linked Data API

Show Search Form

Search Results

967474
star this property registered interest false more like this
star this property date less than 2018-09-04more like thismore than 2018-09-04
star this property answering body
Department of Health and Social Care remove filter
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading Prescription Drugs: Misuse more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government what plans they have to secure funding for existing prescribed medicines withdrawal centres. more like this
star this property tabling member printed
Lord Hunt of Kings Heath more like this
star this property uin HL9967 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2018-09-17more like thismore than 2018-09-17
star this property answer text <p>The Parliamentary under Secretary of State (Steve Brine MP) commissioned Public Health England (PHE) to review the evidence for dependence on, and withdrawal from, prescribed medicines. The review was launched in January 2018 and is due to report in spring 2019 and we await its findings. It is the responsibility of local authorities to commission services, such as the provision of withdrawal centres for addiction to prescribed medicines, to meet assessed local need. The Government currently has no plans to increase the number of these centres.</p><p>The Government has no plans to introduce a separate national helpline to support people affected by prescribed drug dependence. Help and advice on prescribed drug dependence is already available from the 111 helpline or NHS Choices. People who feel that they might be dependent on either prescribed or over the counter medicines should seek help from a health professional in the first instance (such as a general practitioner or pharmacist).</p><p>PHE’s review includes prescribed benzodiazepine drug dependence but will not consider evidence further back than 10 years ago. There are no plans to establish a public inquiry into prescribed benzodiazepine drug dependence.</p>
star this property answering member printed Lord O'Shaughnessy more like this
star this property grouped question UIN
HL9968 more like this
HL9969 more like this
HL9971 more like this
star this property question first answered
less than 2018-09-17T14:06:06.01Zmore like thismore than 2018-09-17T14:06:06.01Z
star this property answering member
4545
star this property label Biography information for Lord O'Shaughnessy more like this
star this property tabling member
2024
star this property label Biography information for Lord Hunt of Kings Heath remove filter
967475
star this property registered interest false more like this
star this property date less than 2018-09-04more like thismore than 2018-09-04
star this property answering body
Department of Health and Social Care remove filter
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading Prescription Drugs: Misuse more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government what plans they have, if any, to increase the number of prescribed medicines withdrawal centres to cover the whole of England. more like this
star this property tabling member printed
Lord Hunt of Kings Heath more like this
star this property uin HL9968 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2018-09-17more like thismore than 2018-09-17
star this property answer text <p>The Parliamentary under Secretary of State (Steve Brine MP) commissioned Public Health England (PHE) to review the evidence for dependence on, and withdrawal from, prescribed medicines. The review was launched in January 2018 and is due to report in spring 2019 and we await its findings. It is the responsibility of local authorities to commission services, such as the provision of withdrawal centres for addiction to prescribed medicines, to meet assessed local need. The Government currently has no plans to increase the number of these centres.</p><p>The Government has no plans to introduce a separate national helpline to support people affected by prescribed drug dependence. Help and advice on prescribed drug dependence is already available from the 111 helpline or NHS Choices. People who feel that they might be dependent on either prescribed or over the counter medicines should seek help from a health professional in the first instance (such as a general practitioner or pharmacist).</p><p>PHE’s review includes prescribed benzodiazepine drug dependence but will not consider evidence further back than 10 years ago. There are no plans to establish a public inquiry into prescribed benzodiazepine drug dependence.</p>
star this property answering member printed Lord O'Shaughnessy more like this
star this property grouped question UIN
HL9967 more like this
HL9969 more like this
HL9971 more like this
star this property question first answered
less than 2018-09-17T14:06:06.08Zmore like thismore than 2018-09-17T14:06:06.08Z
star this property answering member
4545
star this property label Biography information for Lord O'Shaughnessy more like this
star this property tabling member
2024
star this property label Biography information for Lord Hunt of Kings Heath remove filter
967476
star this property registered interest false more like this
star this property date less than 2018-09-04more like thismore than 2018-09-04
star this property answering body
Department of Health and Social Care remove filter
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading Prescription Drugs: Misuse more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government whether they will ensure that in establishing a 24 hour helpline for people affected by prescribed medicines addiction they will also ensure that adequate services are in place to refer patients to. more like this
star this property tabling member printed
Lord Hunt of Kings Heath more like this
star this property uin HL9969 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2018-09-17more like thismore than 2018-09-17
star this property answer text <p>The Parliamentary under Secretary of State (Steve Brine MP) commissioned Public Health England (PHE) to review the evidence for dependence on, and withdrawal from, prescribed medicines. The review was launched in January 2018 and is due to report in spring 2019 and we await its findings. It is the responsibility of local authorities to commission services, such as the provision of withdrawal centres for addiction to prescribed medicines, to meet assessed local need. The Government currently has no plans to increase the number of these centres.</p><p>The Government has no plans to introduce a separate national helpline to support people affected by prescribed drug dependence. Help and advice on prescribed drug dependence is already available from the 111 helpline or NHS Choices. People who feel that they might be dependent on either prescribed or over the counter medicines should seek help from a health professional in the first instance (such as a general practitioner or pharmacist).</p><p>PHE’s review includes prescribed benzodiazepine drug dependence but will not consider evidence further back than 10 years ago. There are no plans to establish a public inquiry into prescribed benzodiazepine drug dependence.</p>
star this property answering member printed Lord O'Shaughnessy more like this
star this property grouped question UIN
HL9967 more like this
HL9968 more like this
HL9971 more like this
star this property question first answered
less than 2018-09-17T14:06:06.143Zmore like thismore than 2018-09-17T14:06:06.143Z
star this property answering member
4545
star this property label Biography information for Lord O'Shaughnessy more like this
star this property tabling member
2024
star this property label Biography information for Lord Hunt of Kings Heath remove filter
967478
star this property registered interest false more like this
star this property date less than 2018-09-04more like thismore than 2018-09-04
star this property answering body
Department of Health and Social Care remove filter
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading Benzodiazepines: Misuse more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government whether they will establish a public inquiry into the harmful effects of prescribed benzodiazepine drug dependence over the last 50 years. more like this
star this property tabling member printed
Lord Hunt of Kings Heath more like this
star this property uin HL9971 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2018-09-17more like thismore than 2018-09-17
star this property answer text <p>The Parliamentary under Secretary of State (Steve Brine MP) commissioned Public Health England (PHE) to review the evidence for dependence on, and withdrawal from, prescribed medicines. The review was launched in January 2018 and is due to report in spring 2019 and we await its findings. It is the responsibility of local authorities to commission services, such as the provision of withdrawal centres for addiction to prescribed medicines, to meet assessed local need. The Government currently has no plans to increase the number of these centres.</p><p>The Government has no plans to introduce a separate national helpline to support people affected by prescribed drug dependence. Help and advice on prescribed drug dependence is already available from the 111 helpline or NHS Choices. People who feel that they might be dependent on either prescribed or over the counter medicines should seek help from a health professional in the first instance (such as a general practitioner or pharmacist).</p><p>PHE’s review includes prescribed benzodiazepine drug dependence but will not consider evidence further back than 10 years ago. There are no plans to establish a public inquiry into prescribed benzodiazepine drug dependence.</p>
star this property answering member printed Lord O'Shaughnessy more like this
star this property grouped question UIN
HL9967 more like this
HL9968 more like this
HL9969 more like this
star this property question first answered
less than 2018-09-17T14:06:06.203Zmore like thismore than 2018-09-17T14:06:06.203Z
star this property answering member
4545
star this property label Biography information for Lord O'Shaughnessy more like this
star this property tabling member
2024
star this property label Biography information for Lord Hunt of Kings Heath remove filter
947564
star this property registered interest false more like this
star this property date less than 2018-07-24more like thismore than 2018-07-24
star this property answering body
Department of Health and Social Care remove filter
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading PrescQIPP more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government what assessment they have made of the accuracy of the information provided by PrescQIPP to Clinical Commissioning Groups to aid their commissioning decisions. more like this
star this property tabling member printed
Lord Hunt of Kings Heath more like this
star this property uin HL9847 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2018-07-26more like thismore than 2018-07-26
star this property answer text <p>We have not made any assessment on the accuracy and advice provided by PrescQIPP. Nor have we made any assessment on whether the advice provided by PrescQIPP to clinical commissioning groups (CCGs) is consistent with national guidelines on the prescription of liothyronine to National Health Service patients. We can confirm that we have not received any assurances from PrescQIPP on whether or not it has taken patient stakeholder views into account as it is the responsibility of CCGs to seek any such assurances.</p><p>PrescQIPP is an independent social enterprise and it is for CCGs to decide whether and how they take that guidance into account when making decisions. However, NHS England expects CCGs to have due regard to the guidance <em>Items which should not routinely be prescribed in primary care: Guidance for CCGs,</em> published in November 2017 by NHS England and NHS Clinical Commissioners when considering the prescribing of liothyronine. A copy of the guidance is attached.</p> more like this
star this property answering member printed Lord O'Shaughnessy more like this
star this property grouped question UIN
HL9848 more like this
HL9849 more like this
star this property question first answered
less than 2018-07-26T12:46:36.65Zmore like thismore than 2018-07-26T12:46:36.65Z
star this property answering member
4545
star this property label Biography information for Lord O'Shaughnessy more like this
star this property attachment
1
star this property file name items-which-should-not-be-routinely-precscribed-in-pc-ccg-guidance.pdf more like this
star this property title Items which should not routinely be prescribed more like this
star this property tabling member
2024
star this property label Biography information for Lord Hunt of Kings Heath remove filter
947566
star this property registered interest false more like this
star this property date less than 2018-07-24more like thismore than 2018-07-24
star this property answering body
Department of Health and Social Care remove filter
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading Liothyronine more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government what assessment they have made of whether the advice provided by PresQIPP to Clinical Commissioning Groups is consistent with national guidelines on the prescription of Liothryonine (T3) to NHS patients. more like this
star this property tabling member printed
Lord Hunt of Kings Heath more like this
star this property uin HL9848 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2018-07-26more like thismore than 2018-07-26
star this property answer text <p>We have not made any assessment on the accuracy and advice provided by PrescQIPP. Nor have we made any assessment on whether the advice provided by PrescQIPP to clinical commissioning groups (CCGs) is consistent with national guidelines on the prescription of liothyronine to National Health Service patients. We can confirm that we have not received any assurances from PrescQIPP on whether or not it has taken patient stakeholder views into account as it is the responsibility of CCGs to seek any such assurances.</p><p>PrescQIPP is an independent social enterprise and it is for CCGs to decide whether and how they take that guidance into account when making decisions. However, NHS England expects CCGs to have due regard to the guidance <em>Items which should not routinely be prescribed in primary care: Guidance for CCGs,</em> published in November 2017 by NHS England and NHS Clinical Commissioners when considering the prescribing of liothyronine. A copy of the guidance is attached.</p> more like this
star this property answering member printed Lord O'Shaughnessy more like this
star this property grouped question UIN
HL9847 more like this
HL9849 more like this
star this property question first answered
less than 2018-07-26T12:46:36.713Zmore like thismore than 2018-07-26T12:46:36.713Z
star this property answering member
4545
star this property label Biography information for Lord O'Shaughnessy more like this
star this property attachment
1
star this property file name items-which-should-not-be-routinely-precscribed-in-pc-ccg-guidance.pdf more like this
star this property title Items which should not routinely be prescribed more like this
star this property tabling member
2024
star this property label Biography information for Lord Hunt of Kings Heath remove filter
947567
star this property registered interest false more like this
star this property date less than 2018-07-24more like thismore than 2018-07-24
star this property answering body
Department of Health and Social Care remove filter
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading PrescQIPP more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government what assurances they have received from PresQIPP that when providing guidance to Clinical Commissioning Groups on commissioning decisions it has taken the views of patient stakeholders into account. more like this
star this property tabling member printed
Lord Hunt of Kings Heath more like this
star this property uin HL9849 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2018-07-26more like thismore than 2018-07-26
star this property answer text <p>We have not made any assessment on the accuracy and advice provided by PrescQIPP. Nor have we made any assessment on whether the advice provided by PrescQIPP to clinical commissioning groups (CCGs) is consistent with national guidelines on the prescription of liothyronine to National Health Service patients. We can confirm that we have not received any assurances from PrescQIPP on whether or not it has taken patient stakeholder views into account as it is the responsibility of CCGs to seek any such assurances.</p><p>PrescQIPP is an independent social enterprise and it is for CCGs to decide whether and how they take that guidance into account when making decisions. However, NHS England expects CCGs to have due regard to the guidance <em>Items which should not routinely be prescribed in primary care: Guidance for CCGs,</em> published in November 2017 by NHS England and NHS Clinical Commissioners when considering the prescribing of liothyronine. A copy of the guidance is attached.</p> more like this
star this property answering member printed Lord O'Shaughnessy more like this
star this property grouped question UIN
HL9847 more like this
HL9848 more like this
star this property question first answered
less than 2018-07-26T12:46:36.573Zmore like thismore than 2018-07-26T12:46:36.573Z
star this property answering member
4545
star this property label Biography information for Lord O'Shaughnessy more like this
star this property attachment
1
star this property file name items-which-should-not-be-routinely-precscribed-in-pc-ccg-guidance.pdf more like this
star this property title Items which should not routinely be prescribed more like this
star this property tabling member
2024
star this property label Biography information for Lord Hunt of Kings Heath remove filter
931632
star this property registered interest false more like this
star this property date less than 2018-06-26more like thismore than 2018-06-26
star this property answering body
Department of Health and Social Care remove filter
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading Liothyronine more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government what action they propose to ensure that the Brighton and Sussex University Hospitals NHS Trust withdraws its policy of no longer making Liothyronine (T3) available to NHS patients, contrary to advice issued by NHS England which sets out the circumstances under which Liothyronine (T3) can be prescribed to new patients and continued for existing patients. more like this
star this property tabling member printed
Lord Hunt of Kings Heath more like this
star this property uin HL8980 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2018-07-10more like thismore than 2018-07-10
star this property answer text <p>The national guidelines advise clinical commissioning groups (CCGs) that local decisions should be made regarding arrangements for the on-going prescribing of liothyronine, taking into account the local needs of the population. While CCGs are expected to have regard to national guidance, they are entitled to develop their own local approaches to its implementation. During a debate on 20 June on the Branded Health Service Medicines (Costs) Regulations, I committed to pursuing further with NHS England ways in which they can clarify the guidelines on the prescribing of liothyronine to CCGs, including looking at whether greater clarity on the criteria for appropriate patient usage is merited.</p><p>The prescribing of Liothyronine (T3) was considered by the Sussex and East Surrey Sustainability and Transformation Partnership (STP) clinical board, which covers Brighton and Sussex University Hospitals, and High Weald, Lewes and Havens CCG, following engagement with primary care clinicians and endocrinologists. Based on the evidence presented, the decision not to routinely prescribe Liothyronine (T3) was supported across the STP region. It was, however, recognised that there would be some exceptions to this and that the use of the individual funding request triage process would be an appropriate mechanism to consider these.</p><p><strong> </strong></p>
star this property answering member printed Lord O'Shaughnessy more like this
star this property grouped question UIN
HL8981 more like this
HL8982 more like this
HL8983 more like this
star this property question first answered
less than 2018-07-10T15:41:18.18Zmore like thismore than 2018-07-10T15:41:18.18Z
star this property answering member
4545
star this property label Biography information for Lord O'Shaughnessy more like this
star this property tabling member
2024
star this property label Biography information for Lord Hunt of Kings Heath remove filter
931633
star this property registered interest false more like this
star this property date less than 2018-06-26more like thismore than 2018-06-26
star this property answering body
Department of Health and Social Care remove filter
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading Liothyronine more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government what action they propose to take to ensure that the High Weald, Lewes and Havens Clinical Commissioning Group withdraws its policy of no longer making Liothyronine (T3) available to NHS patients, contrary to advice issued by NHS England which sets out the circumstances under which Liothyronine (T3) can be prescribed to new patients and continued for existing patients. more like this
star this property tabling member printed
Lord Hunt of Kings Heath more like this
star this property uin HL8981 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2018-07-10more like thismore than 2018-07-10
star this property answer text <p>The national guidelines advise clinical commissioning groups (CCGs) that local decisions should be made regarding arrangements for the on-going prescribing of liothyronine, taking into account the local needs of the population. While CCGs are expected to have regard to national guidance, they are entitled to develop their own local approaches to its implementation. During a debate on 20 June on the Branded Health Service Medicines (Costs) Regulations, I committed to pursuing further with NHS England ways in which they can clarify the guidelines on the prescribing of liothyronine to CCGs, including looking at whether greater clarity on the criteria for appropriate patient usage is merited.</p><p>The prescribing of Liothyronine (T3) was considered by the Sussex and East Surrey Sustainability and Transformation Partnership (STP) clinical board, which covers Brighton and Sussex University Hospitals, and High Weald, Lewes and Havens CCG, following engagement with primary care clinicians and endocrinologists. Based on the evidence presented, the decision not to routinely prescribe Liothyronine (T3) was supported across the STP region. It was, however, recognised that there would be some exceptions to this and that the use of the individual funding request triage process would be an appropriate mechanism to consider these.</p><p><strong> </strong></p>
star this property answering member printed Lord O'Shaughnessy more like this
star this property grouped question UIN
HL8980 more like this
HL8982 more like this
HL8983 more like this
star this property question first answered
less than 2018-07-10T15:41:18.227Zmore like thismore than 2018-07-10T15:41:18.227Z
star this property answering member
4545
star this property label Biography information for Lord O'Shaughnessy more like this
star this property tabling member
2024
star this property label Biography information for Lord Hunt of Kings Heath remove filter
931634
star this property registered interest false more like this
star this property date less than 2018-06-26more like thismore than 2018-06-26
star this property answering body
Department of Health and Social Care remove filter
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading Liothyronine more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government what assessment they have made of the Brighton and Sussex University Hospitals NHS Trust mistakenly stating that the only option for patients wishing to continue Liothyronine (T3) therapy is through the private sector, contrary to advice issued by NHS England which sets out the circumstances under which Liothyronine (T3) can be prescribed to new patients and continued for existing patients. more like this
star this property tabling member printed
Lord Hunt of Kings Heath more like this
star this property uin HL8982 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2018-07-10more like thismore than 2018-07-10
star this property answer text <p>The national guidelines advise clinical commissioning groups (CCGs) that local decisions should be made regarding arrangements for the on-going prescribing of liothyronine, taking into account the local needs of the population. While CCGs are expected to have regard to national guidance, they are entitled to develop their own local approaches to its implementation. During a debate on 20 June on the Branded Health Service Medicines (Costs) Regulations, I committed to pursuing further with NHS England ways in which they can clarify the guidelines on the prescribing of liothyronine to CCGs, including looking at whether greater clarity on the criteria for appropriate patient usage is merited.</p><p>The prescribing of Liothyronine (T3) was considered by the Sussex and East Surrey Sustainability and Transformation Partnership (STP) clinical board, which covers Brighton and Sussex University Hospitals, and High Weald, Lewes and Havens CCG, following engagement with primary care clinicians and endocrinologists. Based on the evidence presented, the decision not to routinely prescribe Liothyronine (T3) was supported across the STP region. It was, however, recognised that there would be some exceptions to this and that the use of the individual funding request triage process would be an appropriate mechanism to consider these.</p><p><strong> </strong></p>
star this property answering member printed Lord O'Shaughnessy more like this
star this property grouped question UIN
HL8980 more like this
HL8981 more like this
HL8983 more like this
star this property question first answered
less than 2018-07-10T15:41:18.117Zmore like thismore than 2018-07-10T15:41:18.117Z
star this property answering member
4545
star this property label Biography information for Lord O'Shaughnessy more like this
star this property tabling member
2024
star this property label Biography information for Lord Hunt of Kings Heath remove filter